GMA 208
Alternative Names: GMA-208Latest Information Update: 27 Nov 2020
At a glance
- Originator Gmax Biopharm
- Class Antineoplastics; Immunoconjugates; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Nasopharyngeal cancer
Most Recent Events
- 03 Nov 2020 GMA 208 is available for licensing as of 03 Nov 2020. http://www.gmaxbiopharm.com/job.html
- 03 Nov 2020 Early research in Nasopharyngeal cancer in China (Parenteral) (Gmax Biopharm pipeline, November 2020)